Pancreatic Cancer News

Pancreatic Cancer News

Adaptive Dynamic Therapy Improves Survival in Pancreatic Cancer

Publish Date July 1, 2022

Perioperative adaptive dynamic therapy can improve overall survival in patients with localized pancreatic cancer, new research suggests.

Sequential nab-P/Gem Followed by Modified FOLFOX Shows Potential in mPDAC

Publish Date June 6, 2022

Sequential nab-P/Gem-mFOLFOX improved overall survival, progression-free survival, and time to progression.

CONKO-007: Chemoradiotherapy Improves Resectability in Locally Advanced Pancreatic Cancer

Publish Date June 6, 2022

Post-induction chemoradiotherapy improved resectability, vs chemotherapy alone, in unresectable, locally advanced pancreatic cancer.

Real-World Data Differ From Trial Data for Some Gastrointestinal Cancer Drugs

Publish Date June 2, 2022

Adding nab-paclitaxel to gemcitabine did not appear to improve survival in a real-world cohort.

Eponyms in Oncology: Von Hippel-Lindau Disease

Publish Date May 25, 2022

This weekly series highlights eponyms in oncology. This week, we explore the history and namesakes of von Hippel-Lindau disease.

Gallstone Disease May Predict Pancreatic Cancer

Publish Date May 18, 2022

Patients with pancreatic cancer were 3 times more likely to have gallstone disease in the year prior to their cancer diagnosis, when compared with non-cancer patients.

Eponyms in Oncology: Zollinger-Ellison Syndrome

Publish Date May 10, 2022

This weekly series highlights eponyms in oncology. This week, we explore the history and namesakes of Zollinger-Ellison syndrome.

Fecal Microbiome Signatures May Predict Pancreatic Ductal Adenocarcinoma

Publish Date May 9, 2022

A team of investigators examined the potential of fecal and salivary microbiota to serve as diagnostic biomarkers for pancreatic ductal adenocarcinoma.

AI Tool May Help Predict Risk for Pancreatic Ductal Adenocarcinoma

Publish Date May 5, 2022

The model uses features in CT scans of the abdomen to help identify patients at high risk of developing pancreatic ductal adenocarcinoma.

BRCA1/2 Variants Associated With More Cancers Than Previously Thought

Publish Date April 27, 2022

Researchers identified associations between pathogenic variants in BRCA1/2 and 7 cancers.

Incidence of Pancreatic Neuroendocrine Tumors on the Rise

Publish Date April 12, 2022

The incidence of pancreatic neuroendocrine tumors is increasing in the United States, but overall survival for these patients is improving.

AI Model Uses EHR Data to Predict Risk of Pancreatic Cancer

Publish Date April 11, 2022

AI models could enable earlier detection of pancreatic cancer and improve treatment options for patients, according to researchers.

Eligibility Criteria Add to Race Gap in Pancreatic Cancer Clinical Trials

Publish Date April 8, 2022

Black patients are disproportionately excluded from participation in pancreatic cancer clinical trials.

Expanding Eligibility for Genetic Testing Reveals Clinically Actionable Variants

Publish Date March 31, 2022

Researchers discovered actionable germline genetic variants in 20% of patients who did not meet genetic testing criteria according to prior guidelines.

Fecal Microbiota-Based Screening Feasible for Pancreatic Cancer

Publish Date March 15, 2022

Fecal metagenomics classifiers proved better than salivary-based classifiers for identifying pancreatic ductal adenocarcinoma.

HTN Meds Tied to Lower Mortality After Pancreatic Cancer Diagnosis

Publish Date March 3, 2022

The mortality risk was lower for patients exposed to ACE inhibitors in first 3 years after pancreatic cancer diagnosis.

Sotorasib May Fulfill Unmet Need in Advanced Pancreatic Cancer

Publish Date February 28, 2022

Sotorasib exhibited antitumor activity in a phase 1/2 trial of pretreated patients with KRAS G12C-mutated, advanced pancreatic cancer.

Model Using Routine Clinical Data May Predict Pancreatic Cancer Risk

Publish Date February 18, 2022

A model using routine clinical information can predict pancreatic ductal adenocarcinoma after diagnosis of impaired fasting glucose.

Neoadjuvant Chemoradiotherapy Improves Long-Term OS in Pancreatic Cancer

Publish Date February 9, 2022

In addition to improved overall survival, patients in the neoadjuvant arm had longer disease-free survival and locoregional failure-free intervals.

Adagrasib Shows Promising Activity in Gastrointestinal Cancers

Publish Date February 4, 2022

In the KRYSTAL-1 trial, adagrasib produced a 100% disease control rate in patients with gastrointestinal cancers.